Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy

Basit Öğe Kaydı
dc.authoridSelamoglu, Zeliha/0000-0001-9056-6435
dc.authoridRasul, Azhar/0000-0001-9669-7364
dc.authoridHUSSAIN, Ghulam/0000-0001-9090-7789
dc.authoridYounis, Tahira/0000-0002-3140-9330
dc.contributor.authorSharif, Farzana
dc.contributor.authorRasul, Azhar
dc.contributor.authorAshraf, Asma
dc.contributor.authorHussain, Ghulam
dc.contributor.authorYounis, Tahira
dc.contributor.authorSarfraz, Iqra
dc.contributor.authorChaudhry, Muhammad Asrar
dc.date.accessioned2024-11-07T13:34:49Z
dc.date.available2024-11-07T13:34:49Z
dc.date.issued2019
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractAltered enzymatic machineries are a substantial biochemical characteristic of tumor cell metabolism that switch metabolic profile from oxidative phosphorylation to amplified glycolysis as well as increased lactate production under hypoxia conditions. Reprogrammed metabolic profile is an emerging hallmark of cancer. Overexpression of several glycolytic enzymes and glucose transporters has been reported in 24 different types of cancers that represent approximately 70% of all the cancer cases around the globe. Thus, targeting glycolytic enzymes could serve as tempting avenue for drug design against cancer. Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate. Recent investigations have revealed the overexpression of PGAM1 in several human cancers that is linked with tumor growth, survival, and invasion. The aim of this review is to update scientific research network with cancer-specific role of PGAM1 to elucidate its capability as bonafide therapeutic target for cancer therapy. Moreover, we have also summarized the reported genetic and pharmacological inhibitors of PGAM1. This study suggests that further investigations on PGAM1 should focus on the exploration of molecular mechanisms of PGAM1 overexpression in development of cancer, assessment of biosafety profiles of known inhibitors of PGAM1, and utilization of PGAM1 inhibitors in combinatorial therapies. These future studies will surely support the unbiased strategies for the development of novel PGAM1 inhibitors for cancer therapies.
dc.identifier.doi10.1002/iub.2100
dc.identifier.endpage1427
dc.identifier.issn1521-6543
dc.identifier.issn1521-6551
dc.identifier.issue10
dc.identifier.pmid31169978
dc.identifier.scopus2-s2.0-85067345545
dc.identifier.scopusqualityQ1
dc.identifier.startpage1418
dc.identifier.urihttps://doi.org/10.1002/iub.2100
dc.identifier.urihttps://hdl.handle.net/11480/16169
dc.identifier.volume71
dc.identifier.wosWOS:000486199700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofIubmb Life
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectcell proliferation
dc.subjectPGAM1
dc.subjecttherapeutic target
dc.subjecttumor growth
dc.titlePhosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu